We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.

The Dow Jones Industrial Average lost 0.6% and the S&P 500 shed 1.1% ahead of tonight’s Federal Reserve interest rate ...

Stocks gained on Wednesday ahead of the Federal Reserve’s interest rate announcement at 2 p.m., which will be followed by Fed ...

The FTSE 100 index is 31.14 points lower at 8674.09, a worse-than-expected performance amid the selling of stocks including ...

The finance sector is strongly represented in this year's attendees. HSBC Group Chief Executive Georges Elhedery is on the ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

In pharmaphorum's Digital and social media themed month, Daniel Ghinn explores GSK's use of social media and the milestones it has reached to achieve its current success in this space. "There's a ...

Last week's rumour that GSK was poised to make a bid to acquire ... The deal coincides with the start of the JP Morgan healthcare conference in San Francisco, which has become a popular venue ...

AGD members are using the population-level insights to uncover novel drug targets SAN DIEGO, /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC (NashBio), a leading clinical ...